Hand sanitizer is not the only product facing high demand. According to Euromonitor2 International, the food market is anticipated to grow at a rate of 3.5% by 2024 in the sauces, dressings, and condiments segments. Consumers are turning to items like shelf-stable foods and other products of necessity. After the acquisition of RPC Group in July of 2019, our Company expanded its portfolio of dispensing closures. Growth within this market enables us to provide a wide array of options for consumers desiring products of importance. In addition, we are currently accelerating our innovative efforts within this space to offer more sizes and orifice options for dispensing and flip-top closures based on recent consumer demand. Our flip-top closures range from 15mm to 53mm with various orifice size and value options. Our flip-top tamper-evident closure, FlipGuard, is another option that can serve the food and home care markets.
Packaging Technology Group has recently expanded it TRUEtemp Naturals® line of cellulose packaging products with the addition of a dual-temperature packaging solution. This first-of-its-kind sustainable packaging allows medications with different temperature requirements to be packaged and carried in the same container. Not only does this shipper preserve the efficacy of thermally-sensitive drugs, but it also provides a more sustainable option to carefully protect and transport medications. The ability to co-contain medicines with varying temperature profiles will surely reduce the amount of material used for packaging itself. This, furthermore, will also save on shipping costs and assembly training and make medication slightly more affordable. Based on PTG’s S4 value proposition, which states their aim to provide Simple, Small, Sustainable and affordable Shipping Solutions, the TRUEtemp Naturals® Cellulose Shippers are: • Made from 100% recycled paper, wood and corrugate • Curbside recyclable, repulpable and biodegradable • EPS equivalent in insulation value The dual temperature property in addition to the existing benefits of the line make the new product truly innovative and sustainable. Currently being applied primarily in the bio-pharmaceutical sector for medicines, this technology can potentially be exposed to other sectors to improve product integrity and promote sustainability.
Multilingual and compact: Schreiner MediPharm supplies booklet labels for clinical studies from Sanofi
Accuracy, safety, efficiency and speed are essential for successful clinical trials. Since the studies are mainly carried out internationally, the investigational medicinal products must be reliably labeled and have all the important information in several languages. Sanofi needed a multi-page label for this, on which the product information is available in many different languages. In addition, it should adhere firmly to the plastic needle protection system and should not affect the functionality of the system. The booklet label developed by Schreiner MediPharm is wrapped closely around the needle protection system. The compact booklet comprises 32 pages with medication information in 22 languages. It adheres reliably to the plastic base of the needle protection system and can be easily wrapped around the square device thanks to the flexible material construction made of thin booklet paper plus layers of film. A grip tab allows the label to be opened and closed comfortably. The booklet label is partially attached to the device so that the pre-filled syringe and its contents are clearly visible after it has been opened. In order to be able to remove the booklet before the injection, it is equipped with a perforation - only a small part of the label, which can contain variable data, for example, remains on the device afterwards. The Schreiner MediPharm Clinical Trial Supplies (CTS) team is a competence and service partner for clinical studies. It has extensive expertise in the field of clinical trial supplies and advises all customers individually and flexibly according to their needs. A specialized process center for booklet labels creates reliable solutions that are optimally adapted to the respective packaging of the investigational medicinal products. About Sanofi Sanofi is a global healthcare company headquartered in Paris with more than 100,000 employees. The group is represented in over 100 countries, with global sales of around 34.5 billion euros in 2018. More than 15,000 Sanofi employees on three continents research and develop new medicines and vaccines.
As part of PepsiCo’s ongoing efforts to provide relief to people and communities impacted by COVID-19, PepsiCo partnered with Product Ventures’ Prototyping and Realization Lab in Plano, Texas to provide face shields to healthcare workers. As local communities were reporting a shortage of personal protective equipment (PPE) to use in their fight against COVID-19, PepsiCo and the Product Ventures team were able to leverage their long-term relationship to quickly assemble the right people, resources, materials and equipment to address this issue. Volunteers from both companies convened at PepsiCo’s Plano lab facility, a sanitary, food-safe environment, to fabricate, package, and ship these face shields to local hospitals including the Lehigh Valley Hospital in Allentown, Pennsylvania, which is on the frontlines of responding to the pandemic.
“We’re so grateful for our ongoing relationship with PepsiCo and are proud of the partnership demonstrated in response to this challenge,” said Peter Clarke, CEO and founder of Product Ventures. “Our designers regularly face condensed timelines and deliver quick and clever solutions to difficult problems, so we were uniquely positioned to react to this crisis and provide help.
” The team developed over 20 iterations of the design. Scalability was a driving factor in their design approach to ensure demand could be easily met. The co-lab’s design can be manufactured in high quantities using different gauges of PET in case of potential shortages. This adaptable approach maintains the scalability without compromising the protection of the face shield.
The packaging design was given careful consideration early in the process to enable quick and easy distribution. One 12 in. x 14 in. x 6 in. box contains 120 flat face shields, more than four times the quantity in a box of standard face shields. This one box can be carried by a single person, allowing for easy and efficient access, distribution, and storage.
This is just a small part of PepsiCo’s broader relief efforts, which include a commitment of more than $50 million focused on serving nutritious meals to people impacted by COVID-19 and providing vital support for healthcare workers, as well as testing and screening services.
Face shields are being offered to medical professionals in Connecticut, Illinois, New Jersey, New York, Pennsylvania, and other states as needed. They are currently being manufactured in PepsiCo’s Plano, Texas and Barrington, Illinois locations. Between the two facilities, more than 2,000 face shields have already been produced and the team has the capability to quickly manufacture more if needed.
Stuttgart, Germany, May 5, 2020 - The Red Dot Jury has made its decision: The D-Flex® emerged victorious from the Red Dot Award: Product Design 2020 and won a Red Dot for its good design quality. This means that the Haselmeier Group is one of the winners in the world’s most renowned design competition.
Multi-Lingual and Compact: Schreiner MediPharm Supplies Booklet-Label for Clinical Trial at Sanofi
Oberschleissheim, May 7, 2020 – Schreiner MediPharm has developed a compact Booklet-Label for a needle protection system used in an international phase III clinical trial conducted by pharmaceutical corporation Sanofi. On more than 30 pages, the extensive yet small booklet contains all the required product information in more than 20 languages.
A device master file provides regulatory authorities with proprietary data about a material, component or manufacturing process. It enables the company submitting the information to the FDA to comply with regulatory requirements for trading in the USA while protecting its intellectual property from potential partners, competitors and customers. Moreover, it facilitates combination product approvals for multiple applications using the same device. Haselmeier formally submitted the MAF for D-Flex in late 2019, following productive discussions with the FDA. Pharmaceutical customers can now refer directly to the master file number MAF3202 when submitting their own products based on the D-Flex pen for approval, greatly simplifying and streamlining the FDA clearance process. With this documentation in place, customers worldwide will be able to leverage the patent-registered D-Flex disposable pen system for their combination product development. This versatile, reliable platform is configurable for several fixed doses, bridging the gap between fixed and variable-dose pens, and can support pharmaceutical customers from clinical trials through to commercial use. Konrad Betzler, Vice President Quality and Alexander Ball, Vice President IT, were involved in the FDA talks. As Mr Betzler comments, “We are delighted that global pharmaceutical customers can now benefit from this device master file submission. The file is a ‘living document’ that will evolve over the months and years ahead, in line with the latest D-Flex capacity and capability enhancements.” In addition to the D-Flex injection system, Haselmeier also presented its D-Flex Connect system to the FDA. D-Flex Connect comprises the D-Flex pen, a smart cap and an innovative, future-proof software platform. This development illustrates Haselmeier’s active commitment to digitalization. Following positive initial conversations with the FDA, Haselmeier plans to compile the data for either 510(k) or IDE submissions by the end of 2020, with the goal of enabling its customers to deploy D-Flex Connect in clinical trials. As Mr Ball remarks, “We are grateful to the FDA for their active and encouraging participation in the meetings held so far. This is an important step for Haselmeier’s expansion into smart data management for therapy efficiency by building the D-Flex Connect platform.” About Haselmeier Haselmeier, headquartered in Switzerland, is a leading provider of subcutaneous injection system solutions. As a reliable development partner, Haselmeier provides customized solutions from concept design and prototyping to engineering and industrialization, including pharmaceutical packaging solutions. Haselmeier empowers safe self-administration of liquid drugs through the development and manufacture of intelligent injection devices that improve therapy efficiency. Moreover, the company is actively developing innovative connected solutions that will help shape the future of smart healthcare. Haselmeier currently employs 240 staff members in six countries with distribution offices in Europe, the US and India, and state-of-the-art manufacturing plants in Buchen, Odenwald, Germany, Dnešice, Czech Republic and Bengaluru, India. Haselmeier unites 100 years of experience in medical technology. For further information, please visit www.haselmeier.com. Contact Silvia Wilkes, Marketing Coordinator email@example.com
In addition to his role as Chair of the Executive Team, Dr. Marco Linari will be responsible for Marketing and Sales, Project Management, Quality Management and IT. As Executive Team Dr. Marco Linari, the Chief Financial Officer (CFO) Mark Bleckmann and the Chief Operations Officer (COO) Matthias Meissner are leading the Haselmeier Group. Dr. Marco Linari studied chemistry and economics and holds a doctorate in biochemistry. After a successful track in strategy consulting, Dr. Marco Linari held national and international leadership roles within the Merck Group in the last 15 year, lastly as CEO of Allergopharma. Through his experience and knowledge of the pharmaceutical and med tech sector, he knows the requirements and needs of the pharma and Med Tech industry. The Haselmeier Group will benefit from his expertise and will have an excellent perspective for its successful further development.
Aptar Requests U.S. FDA Emergency Use Authorization for N95 Filtering Facepiece Respirator Decontamination with ActivShieldTM
In this simple disinfecting process, the N95 mask and a small strip of Aptar’s ActivShieldTM are placed inside any commonly available one-gallon plastic bag. The strip releases a controlled amount of chlorine dioxide inside the sealed bag to decontaminate the N95 mask. The process takes only three hours until the mask is ready to wear again. It can be performed on-site at the local hospital where the mask is being used. Aptar has submitted its safety and effectiveness data to the FDA for EUA review. The company is working to provide approximately four million ActivShield strips per week and is working to expand its production capacity with the intent to deliver ten million per week by the end of April. “We are extremely encouraged by the promising data generated so far and are eager to deliver this technology to the front line and support the fight against the pandemic,” said John Belfance, President of Aptar CSP Technologies. If the FDA approves the EUA, then ActivShield will immediately become available for this important use. Chlorine dioxide has been widely used as a disinfectant in different industries, including the paper industry, drinking water treatment, food processing, and medical equipment. Aptar’s delivery mechanism uses the disinfecting properties of chlorine dioxide in a controlled sustained release within a contained volume. This innovative patent pending technology can efficiently and effectively disinfect N95 masks used by healthcare workers and first responders. “Aptar’s technology provides a unique, simple, and effective way to help solve the critical problem of PPE shortages we’re currently facing,” said Stephan Tanda, Aptar President and CEO. “We are aiming to provide a solution that is not only fast, but it does not require special equipment or training, making it potentially accessible to the wider healthcare community. This could enable healthcare workers to retain and disinfect their own facemask, helping to maintain continued proper fit to their face.”
After a very successful 6th edition, the 7th edition of PharmaLytica will be held in the heartland of Pharma industry in India i.e. Mumbai from 9-11 Sep, 2020 at the Bombay Exhibition Centre in Goregaon (E). At this international trade fair, Pharmaceutical community can pick up on the latest industry trends, innovations and do business with Pharma Machinery & Packaging, Lab Analytical & Cleanroom and Pharma Ingredients segments. For the first time ever, the 6th edition will see a new pavilion for API and Excipients. PharmaLytica is evolving as the leading marketplace for products and services along the entire value chain in niche segments within the Pharma industry.
Key Highlights of PharmaLytica:
• 300+ exhibitors
• 12000 sqm of business space
• Pre fixed B2B meetings
• API and Excipients pavilion
• Stay abreast with latest industry trends & innovations
• Meet and network with leading global suppliers
• Ideal platform for you to grow your business in pharmaceutical capital of India
• It is where the industry's key players and decision-makers meet.
- INDUSTRY UPDATES
- OUR PRODUCTS
- Our Partners